Bayer’s AskBio unit has reported the first clinical data for its congestive heart failure gene therapy, showing preliminary signs of efficacy with no serious adverse events linked to the treatment.

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Charlene Rhinehart is a CPA , CFE, chair of ...

Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. Charlene Rhinehart is a CPA , CFE, ...

Get ready to add Zootopia 2 to your upcoming Disney movies list, as we’re about to head back to the city as one of the late releases on the 2025 movie schedule. It’s hard to believe it’s already been ...

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced it will present initial safety data from the first cohort of participants ...

-- Data from first cohort of five participants suggest an acceptable safety profile for AB-1003 in participants with limb-girdle muscular dystrophy (LGMD) 2I/R9, with no dose-limiting toxicities or ...

myuniversity-cs101-fall2025-fundamental-of-programing--python-student-card-template myuniversity-cs101-fall2025-fundamental-of-programing--python-student-card ...

Type 2 diabetes is a chronic condition characterized by high blood glucose levels, resulting from the body’s ineffective response to insulin or insufficient insulin production. Symptoms of type 2 ...